{
    "nct_id": "NCT04614363",
    "official_title": "Comparison of 68 Ga-PSMA Positron Emission Tomography (PET)/CT to Conventional Imaging in Men With High Risk Prostate Cancer",
    "inclusion_criteria": "* Male aged 21 years or older\n* Ability to understand and provide written informed consent\n* All patients must have histopathological proven adenocarcinoma of the prostate\n* ECOG performance status 0-1\n* No evidence of other malignancy (except squamous or basal cell skin cancers)\n* Consent to use acceptable form of birth control following the imaging period (condoms for a period of seven days after injection if sexually active)\n\nA. Inclusion criteria specific for the pre-prostatectomy group:\n\nUntreated prostate Cancer with high-risk features, as defined as having at least one of the following criteria:\n\ni. PSA â‰¥ 20.0 ng/mL ii. ISUP Gleason Grade Group 3, 4 or 5 iii. Clinical stage T3\n\nB. Inclusion criteria specific for biochemical recurrence:\n\n(i) Histopathological proven prostate adenocarcinoma (ii)Rising PSA after definitive therapy with prostatectomy or radiation (therapy (external beam or brachytherapy).\n\n1. Post radical prostatectomy (RP), PSA greater than or equal to 0.2 ng/ml measured more than 6 weeks after RP.\n2. Post-radiation therapy, PSA that is equal to or greater than 2 ng/ml rise above PSA nadir\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 21 Years",
    "exclusion_criteria": "* Unable to tolerate a PET/CT (e.g. unable to lie flat)\n* Recent history of a secondary malignancy in the past year, excluding non-melanoma skin cancer (non-metastatic)\n* Known allergic reactions to 68-Ga, or gadolinium-based contrast agents.\n* Treatment with another investigational drug or other intervention 2 years.\n* Patient has any medical, psychological or social condition that, in opinion of the investigator will make difficult for the participant to tolerate study intervention.",
    "miscellaneous_criteria": ""
}